CSLLY Csl Ltd Sponsored ADRs

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:CSL.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$98.18    Pink
As of 01/18/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  11/21/2018
Outstanding shares:  957,496,782
Average volume:  51,690
Market cap:   $95,519,878,972
Current dividend yield:  1.18%
Sedol:      
Valuation   (See tab for details)
PE ratio:   47.62
PB ratio:   10.83
PS ratio:   10.68
Return on equity:   23.93%
Net income %:   22.43%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy